Swiss finish
18 April 2012

The Swiss drugmaker is walking away after failing to cajole the gene-sequencing firm into talks. Shareholders clearly weren’t pushing Illumina to the table, and a wobble in its shares now won’t change that. But Roche could return if the stock continues to languish.